Artificial intelligence-based compound-viral proteins interaction framework, will be used via a transfer learning setting to prioritize a set of FDA approved and investigational drugs which can potentially inhibit a specific viral proteins. To filter and narrow down the lead compounds from curated collections of pharmaceutical compounds, we use a rigorous computational framework that included homology modeling, molecular docking, dynamic simulations, binding free energy calculations, and binding pose metadynamics. We identified Elvitegravir as a potential inhibitor of the virus using our comprehensive pipeline.